Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project

作者：Bria Midgette, Andrew Strunk, Oleg E. Akilov, Afsáneh Alavi, Christine B. Ardon, Falk G. Bechara, Arnon D. Cohen, Steven A. Cohen, Steven Daveluy, V. del Mármol, M. Delage, Solveig Esmann, Shani Fisher, Evangelos J. Giamarellos‐Bourboulis, Amelia Głowaczewska, Noah Goldfarb, Elena Gonzalez Brant, Øystein Grimstad, Sandra Guilbault, Iltefat Hamzavi, Rosalind Hughes, John R Ingram, Gregor B. E. Jemec, Qiang Ju, Naomi Kappe, Brian Kirby, Joslyn S. Kirby, Michelle A. Lowes, Łukasz Matusiak, Stella Micha, Robert G. Micheletti, Angela P. Miller, Dagfinn Moseng, Haley B. Naik, Aude Nassif, Georgios Nikolakis, So Yeon Paek, J.C. Pascual, Errol P. Prens, Barry I. Resnik, Hassan Riad, Christopher J. Sayed, Saxon D. Smith, Yssra Soliman, Jacek C. Szepietowski, Jerry Tan, Linnea Thorlacius, Thrasyvoulos Tzellos, Hessel H. van der Zee, Bente Villumsen, Lanqi Wang, Christos C. Zouboulis, Amit Garg · 发表于：British Journal of Dermatology · 年份：2022 · DOI：10.1111/bjd.21798 · 被引用次数：30 · 研究领域：Hidradenitis Suppurativa and Treatments、Acne and Rosacea Treatments and Effects、Anorectal Disease Treatments and Outcomes

BACKGROUND: Nearly half of patients with hidradenitis suppurativa (HS) report dissatisfaction with their treatment. However, factors related to treatment satisfaction have not been explored. OBJECTIVES: To measure associations between treatment satisfaction and clinical and treatment-related characteristics among patients with HS. METHODS: Treatment satisfaction was evaluated utilizing data from a cross-sectional global survey of patients with HS recruited from 27 institutions, mainly HS referral centres, in 14 different countries from October 2017 to July 2018. The primary outcome was patients' self-reported overall satisfaction with their current treatments for HS, rated on a five-point scale from 'very dissatisfied' to 'very satisfied'. RESULTS: The final analysis cohort comprised 1418 patients with HS, most of whom were European (55%, 780 of 1418) or North American (38%, 542 of 1418), and female (85%, 1210 of 1418). Overall, 45% (640 of 1418) of participants were either dissatisfied or very dissatisfied with their current medical treatment. In adjusted analysis, patients primarily treated by a dermatologist for HS had 1·99 [95% confidence interval (CI) 1·62-2·44, P < 0·001] times the odds of being satisfied with current treatment than participants not primarily treated by a dermatologist. Treatment with biologics was associated with higher satisfaction [odds ratio (OR) 2·36, 95% CI 1·74-3·19, P < 0·001] relative to treatment with nonbiologic systemic medications. Factors ...